Study of Rebinyn for boys and men with Hemophilia B
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study follows males with Hemophilia B who are already on preventive (prophylaxis) treatment with Rebinyn/Refixia (a factor replacement medicine). It mainly looks at safety and how treatment is used over time, especially in people starting or continuing this prophylaxis plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your legally authorized representative) must sign consent before any study activities.
- You are a male with Hemophilia B on prevention treatment called N9-GP (Refixia/Rebinyn).
- Your care team has already decided to start commercial N9-GP before joining the study.
- You have not signed up for this same study before.
- You do not have a known or suspected allergy to Rebinyn/Refixia or related products.
- You do not have a suspected or confirmed inhibitor to factor IX (often called an “anti-FIX inhibitor”).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows male participants with hemophilia A who are already taking Esperoct® as preventive (regular) treatment. It aims to learn how well this medicine works in real-world use and monitor safety over time.
This study watches how well HEMGENIX works and how safe it is for people with hemophilia B who are getting the treatment. It also compares data from adults on standard factor IX shots.
This trial tests a new gene therapy (REGV131-LNP1265) that aims to let your body produce its own factor IX, reducing or stopping the need for regular infusions. It is for children and adults with severe hemophilia B who are already using factor IX replacement therapy.
This study tests a new gene therapy called ANB-002 for men with severe hemophilia B (factor IX levels at or below 2%). The goal is to see if it's safe and how well it might help your blood clot normally.
This trial tests a single dose of ANB-002, an experimental therapy for hemophilia B. It aims to see if the drug is safe and effective for people with severe hemophilia B who have been treated with factor IX before and do not have inhibitors.
This trial tests a new drug called KN057 for people with severe hemophilia A or moderate-to-severe hemophilia B, whether or not they have developed inhibitors (antibodies that block standard treatments). The goal is to see if it can help prevent or treat bleeding episodes.
Hear when a new Haemophilia B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.